Drug manufacturer Zydus Lifesciences Ltd announced on Tuesday, December 9, that its subsidiary, Zydus Lifesciences Global FZE in the UAE, has formed a strategic alliance with Formycon AG for the exclusive licensing and supply of FYB206, a biosimilar of the immunotherapy drug Keytruda. Formycon AG will be in charge of the product’s development, registration, manufacturing, and supply, while Zydus Lifesciences Global FZE will oversee the commercialization of FYB206 specifically in the US and Canada. The closing price of Zydus Lifesciences Ltd shares on the Bombay Stock Exchange (BSE) on December 9 was ₹920, showing a decrease of ₹4.60 or 0.50%. This partnership aims to bring a cost-effective alternative to patients in need of Keytruda in the US and Canada.
Zydus Life unit partners with Formycon to supply immunotherapy drug Keytruda biosimilar in US, Canada
-
Flamengo and PSG have faced each other three times; check out their record
-
Indonesia Open Footgolf Tournament: Comedian Oki Rengga Admits Addiction, Wants to Become a Professional Athlete
-
Shameful Incident in Punjab! Landlord Rolls Tenant’s Daughter
-
Virgil van Dijk Expresses Desire for Mohamed Salah to Stay at Liverpool
Deixe um comentário